Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

Foley Hoag Secures Win for Dana-Farber Cancer Institute on Challenge to Inventorship of Groundbreaking Cancer Immunotherapy PatentsOpen in a New Window

BOSTON--(BUSINESS WIRE)--The U.S. District Court ruled in favor of Foley Hoag LLP’s client, Dana-Farber Cancer Institute, that Dana-Farber scientist, Gordon Freeman, PhD, and another scientist, Clive Wood, PhD, are co-inventors on a series of cancer immunotherapy patents previously issued to a Japanese researcher and Japanese drug company. The ruling directs that the patents be corrected to name Freeman and Wood as inventors. In her decision, Chief Judge Patti B. Saris wrote that “Dana-Farber h

 

Physicians’ Education Resource® to Host ASCO Direct™ Highlights in Kansas CityOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Breast?src=hash" target="_blank"gt;#Breastlt;/agt;--Physicians’ Education Resource® to Host ASCO Direct™ Highlights in Kansas City

 

Florida Research Institute & Echosens Present Research Studies at May 2019 Digestive Disease Week: Highlights Value of Non-Invasive Screening for Fatty Liver DiseaseOpen in a New Window

SAN DIEGO & WALTHAM, Mass.--(BUSINESS WIRE)--Echosens Presents Research Studies at May 2019 Digestive Disease Week: Highlights Value of Non-Invasive Screening for Fatty Liver Disease

 

Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast CancerOpen in a New Window

REHOVOT, Israel & WILMINGTON, Del.---(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically defined, today announced updates on AL101, a pan-Notch inhibitor, that will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Il. The details of the poster presentations are as follows: Title: ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/met

 

PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing ProcessOpen in a New Window

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/INDstatus?src=hash" target="_blank"gt;#INDstatuslt;/agt;--PharmaCyte proceeding with GMP production of pancreatic cancer product after successful changes to manufacturing process.

 

MyHeritage Expands to Health; Launches New DNA Test Offering Powerful and Personalized Health Insights for ConsumersOpen in a New Window

TEL AVIV, Israel & LEHI, Utah--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/dna?src=hash" target="_blank"gt;#dnalt;/agt;--MyHeritage Expands to Health; Launches New DNA Test Offering Powerful and Personalized Health Insights for Consumers.

 

State of Nebraska Selects NIC Inc.’s RxGov® as Its New Prescription Drug Monitoring PlatformOpen in a New Window

OLATHE, Kan.--(BUSINESS WIRE)--NIC Inc. has been selected to provide its RxGov prescription drug monitoring platform to the State of Nebraska.

 

Cheetah Medical Showcases Fluid Management Education with Virtual Trainer App at the 2019 National Teaching Institute & Critical Care ExpositionOpen in a New Window

NEWTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/NTI2019?src=hash" target="_blank"gt;#NTI2019lt;/agt;--Cheetah Medical showcases fluid management education with Virtual Trainer app at the 2019 National Teaching Institute & Critical Care Exposition

 

Earth Networks Releases 2019 Hurricane OutlookOpen in a New Window

GERMANTOWN, Md.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/hurricane?src=hash" target="_blank"gt;#hurricanelt;/agt;--Earth Networks released its 2019 Atlantic Hurricane Season Outlook.

 

Categorical Response and Clinical Relevance as Assessed in a Phase III Study of HP-3070 (Asenapine) Transdermal Patch for the Treatment of Schizophrenia to be Presented at the American Psychiatric Association 172nd Annual MeetingOpen in a New Window

MIAMI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Ltd., announced today that secondary endpoint data from the pivotal Phase III study for HP-3070 (asenapine) transdermal drug delivery system (TDDS), an investigational product for the treatment of schizophrenia, will be featured as a poster presentation at the American Psychiatric Association (APA) 172nd Annual Meeting in San Francisco, May 18 – 22, 2019. This post

 

iSchemaView Launches RAPID UOpen in a New Window

MENLO PARK, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/RAPIDai?src=hash" target="_blank"gt;#RAPIDailt;/agt;--iSchemaView, the worldwide leader in advanced imaging for stroke, has launched RAPID U, a training certification program for the RAPID platform.

 

Genomind Launches the Most Comprehensive Genetics-Based Mental Health Test Available, Genomind Professional PGx, to Help Clinicians Optimize Mental Health Medication DecisionsOpen in a New Window

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind – a leading mental health care company – today announced that its flagship pharmacogenetic product, Genomind Professional PGx™, is now available to patients through their health care providers. Genomind Professional PGx provides personalized analytics on patient-specific genetic markers. This information helps indicate which medications or other treatment options, for more than 11 mental health conditions, are better suited for a patient based on

 

Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 BillionOpen in a New Window

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. With the addition of Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vect

 

Zoetis to Participate in the Stifel 2019 Dental & Veterinary ConferenceOpen in a New Window

PARSIPPANY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ZTS&src=ctag" target="_blank"gt;$ZTSlt;/agt; lt;a href="https://twitter.com/hashtag/animalhealth?src=hash" target="_blank"gt;#animalhealthlt;/agt;--Zoetis Inc. will present at the Stifel 2019 Dental & Veterinary Conference on May 29 at 10:30 am ET.

 

DNAnexus Appoints David Fenstermacher as Vice President of Precision Medicine and Data SciencesOpen in a New Window

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/bioinformatics?src=hash" target="_blank"gt;#bioinformaticslt;/agt;--DNAnexus Appoints David Fenstermacher as Vice President of Precision Medicine and Data Sciences

 

Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer DiagnosisOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis

 

Personalis Enters into a Research Agreement with FLX Bio to Provide Comprehensive Tumor Immunogenomic Profiling for Clinical StudyOpen in a New Window

MENLO PARK, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IOCombos360?src=hash" target="_blank"gt;#IOCombos360lt;/agt;--Personalis Enters into a Research Agreement with FLX Bio to Provide Comprehensive Tumor Immunogenomic Profiling for Clinical Study.

 

DNAnexus Appoints Scott Gibson as Chief Financial OfficerOpen in a New Window

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/bioinformatics?src=hash" target="_blank"gt;#bioinformaticslt;/agt;--DNAnexus Appoints Scott Gibson as Chief Financial Officer

 

Savonix to Present at Upcoming Industry & Scientific ConferencesOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Savonix to Present at Upcoming Industry & Scientific Conferences

 

National Cancer Institute Implements Cloud-First Data Protection with DruvaOpen in a New Window

SUNNYVALE, Calif.--(BUSINESS WIRE)--Druva, Inc., the leader in cloud data protection and management, today announced the National Cancer Institute (NCI), the federal government's primary agency addressing cancer research and treatment, is using Druva to replace its legacy hardware solutions for backup, restore and archiving of data. As the only FedRAMP certified data management solution, Druva’s unique technology ensures compliance with stringent government regulations and ease of management wi

 

FASENRA® (benralizumab) reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthmaOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--A new integrated analysis of Phase III data for FASENRA® (benralizumab) shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids (OCS) and experienced a sustained improvement in exacerbation rates, lung function, asthma control and health-related quality of life. The analysis, presented today at the American Thoracic Society (ATS) 2019 International Confere

 

Surescripts Expands White Coat Award to Recognize Health System, Pharmacy and EHR Leaders for Improving Prescription AccuracyOpen in a New Window

ARLINGTON, Va.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/EHR?src=hash" target="_blank"gt;#EHRlt;/agt;--Expanded award eligibility and updated criteria elevate industry leaders who make meaningful changes to enhance patient safety and healthcare delivery

 

Saama Challenges Analytics Industry to Guarantee Data Platforms to Help Accelerate Drug DevelopmentOpen in a New Window

CAMPBELL, Calif.--(BUSINESS WIRE)--Saama challenges analytics industry to guarantee data platforms to accelerate drug development; Saama Guarantee leads this call-to-action.

 

Oragenics, Inc. Provides Development Update of AG013 for Oral MucositisOpen in a New Window

TAMPA, Fla.--(BUSINESS WIRE)--Phase 2 Clinical Trial Enrollment Progresses While World Health Organization Provides Generic Name of AG013 Compound

 

Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of DermatologyOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announces that data from key studies within its inflammation and autoimmunity portfolio will be presented at the 24th World Congress of Dermatology (WCD). This meeting will be held in Milan, Italy from June 10-15, 2019. Presentations will feature 24-week data from a Phase 2 study of ruxolitinib cream in adult patients with vitiligo, which will be highlighted during the late-breaking research session, and 12-week data from a Pha

 

KalVista Pharmaceuticals to Present Data at Upcoming Scientific ConferencesOpen in a New Window

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24KALV&src=ctag" target="_blank"gt;$KALVlt;/agt;--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that data has been accepted for presentation at both the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary and European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal. “We are excited to present

 

Kraig Biocraft Laboratories Takes Possession of Factory in VietnamOpen in a New Window

ANN ARBOR, Mich.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24KBLB&src=ctag" target="_blank"gt;$KBLBlt;/agt; lt;a href="https://twitter.com/hashtag/KBLB?src=hash" target="_blank"gt;#KBLBlt;/agt;--Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its subsidiary Prodigy Textiles has taken possession of its factory in Vietnam. The Company is now retrofitting the nearly 50,000 square foot facility to produce its game changing recombinant spider silk materials. Remodeling efforts are expected to be minimal and completed quickly. This facility was selected based on its optimal

 

PROCEPT BioRobotics® Announces New Clinical and Real-World Data Highlighting Effectiveness, Durability, Superior Safety and Reproducibility of Aquablation® Therapy for BPHOpen in a New Window

REDWOOD SHORES, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AUA19?src=hash" target="_blank"gt;#AUA19lt;/agt;--New clinical data presented at AUA 2019 position PROCEPT BioRobotics' Aquablation therapy as new standard of care for patients suffering from BPH.

 

Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)Open in a New Window

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)

 

Intact Vascular to Sponsor Post-Angioplasty Dissection Symposium at 2019 New Cardiovascular Horizons ConferenceOpen in a New Window

WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the schedule of key presentations to be featured during a lunch symposium at the 2019 New Cardiovascular Horizons (NCVH) Conference, May 29th through 31st at The Roosevelt New Orleans in New Orleans, Louisiana. Recently FDA-approved for above-the-knee interventions, the Tack Endovascular System is a first-of-its-kind dissection repair device i

 

Corindus to Showcase CorPath® GRX Robotic System at EuroPCR 2019Open in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Clinique Pasteur is first European site to adopt latest CorPath GRX vascular robotic technology; Corindus to showcase technology at EuroPCR 2019

 

SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid TumorsOpen in a New Window

STAMFORD, Conn.--(BUSINESS WIRE)--SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors

 

Magellan Rx Management’s Second Annual Employer Market Insights Report Highlights Market Dynamics and Opportunities for Traditional and Specialty DrugsOpen in a New Window

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Magellan Rx Management released its second Employer Market Insights Report, which highlights key areas of pharmacy trend and spend.

 

Inteliquet Signs Cooperative R&D Agreement (CRADA) with the National Cancer InstituteOpen in a New Window

MEMPHIS, Tenn.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Cancer?src=hash" target="_blank"gt;#Cancerlt;/agt;--Inteliquet has entered into a Cooperative Research and Development Agreement with NCI.

 

Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019Open in a New Window

MENLO PARK, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/immuno19?src=hash" target="_blank"gt;#immuno19lt;/agt;--Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019: Advancing Precision Oncology Biomarker Discovery with ImmunoID NeXT.

 

New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During SurgeryOpen in a New Window

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study evaluates the ability of Masimo SpHb® (noninvasive hemoglobin) to help clinicians estimate when to conduct invasive measurement.

 

QIAGEN Gains 510(k) Clearance by FDA for QIAstat-Dx in the U.S. and Launches System as Next Generation Platform for Syndromic InsightsOpen in a New Window

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the U.S. launch of its QIAstat-Dx syndromic testing system after receiving 510(k) clearance by the U.S. Food and Drug Administration, along with the multiplex QIAstat-Dx® Respiratory Panel for simultaneous qualitative detection and identification of multiple respiratory viral and bacterial pathogens. QIAstat-Dx (formerly Stat-Dx DiagCORE®) represents the next-generation in m

 

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously ThoughtOpen in a New Window

DALLAS--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24RMD&src=ctag" target="_blank"gt;$RMDlt;/agt; lt;a href="https://twitter.com/hashtag/CPAP?src=hash" target="_blank"gt;#CPAPlt;/agt;--A million-patient study reveals gaps among various sub-populations in long-term adherence to CPAP for treating sleep apnea.

 

DDW 2019: New Study Shows SonarMD Lowers Cost of Managing Crohn’s DiseaseOpen in a New Window

CHICAGO--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/DDW19?src=hash" target="_blank"gt;#DDW19lt;/agt;--New study shows SonarMD’s care coordination solution helps lower cost of managing Crohn’s disease.

 

Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week by Researchers from Massachusetts General Hospital and Brigham and Women’s HospitalOpen in a New Window

BOSTON--(BUSINESS WIRE)--Gelesis announced the presentation of data from a clinical study of GS500 for potential treatment of chronic constipation at Digestive Disease Week.

 

About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

NEW regional sponsorship opportunities available.

Connect